A Case of Metastatic Adamantinoma That Responded Well to Sunitinib. (17th August 2016)

• Record Type: Journal Article
• Authors: Liman, Andrew D.; Liman, Agnes K.; Shields, Jenna; Englert, Becky; Shah, Rashmikant
• Other Names: Lenehan Peter F. Academic Editor.
• Is Part Of: Case reports in oncological medicine. Volume 2016(2016)
• Publication Date: 2016-08-17
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Oncology -- Case studies -- Periodicals; Neoplasms; Oncology; Tumors; Electronic journals; Periodicals; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.994
• DOI: 10.1155/2016/5982313
• Languages: English
• ISSNs: 2090-6706

Abstract

Abstract : Adamantinoma is a rare low-grade malignant bone tumor of epithelial origin. Metastatic adamantinoma has been reported to be resistant to chemotherapy. We report a case of metastatic adamantinoma to the lung, 10 years after the initial diagnosis of tibial mass. The patient received radiation therapy to the lung with partial response. A surveillance PET scan revealed progression of the lung mass and biopsy confirmed to be progressive residual metastatic adamantinoma. He received carboplatin and etoposide for 7 months and achieved a partial response. Four months later, PET scan showed disease progression. We started him on sunitinib, a multikinase inhibitor. He achieved a good partial response for 3 years. He died due to pneumonia at the age of 72.